Wu Y-L, Guarneri V, Voon PJ, et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol 2024; 25: 989–1002—In figure 2A of this Article, colour coding in the graph has been corrected. In figure 2B, points for partial response and disease progression have been corrected. In figure 3A, for progression-free survival by independent review committee, colour coding for patients with no response has been corrected.